exacerbations

Moxifloxacin hydrochloride (BAY12-8039 HCl) is a fourth generation fluoroquinolone with expanded activity against gram-positive bacteria as well as atypical pathogens. Moxifloxacin has been linked to mild ALT elevations during therapy and to rare instances of idiosyncratic acute liver injury with symptoms and jaundice.

Benralizumab (MEDI-563) is a monoclonal antibody targeting the interleukin-5 receptor alpha (IL-5Rα). It enhances antibody-dependent cell-mediated cytotoxicity, leading to a rapid depletion of eosinophils. Benralizumab is used for severe eosinophilic asthma and can be employed to prevent exacerbations of chronic obstructive pulmonary disease.

Cefdinir is an advanced broad-spectrum cephalosporin antibacterial compound approved for treating community-acquired pneumonia, acute bacterial exacerbations of chronic bronchitis, acute maxillary sinusitis, pharyngitis tonsillitis, acute bacterial otitis media, and uncomplicated skin and skin structure infections in both adult and pediatric patients.

Moxifloxacin-d4 hydrochloride (BAY 12-8039-d4) is the hydrochloride salt form of deuterium-labeled Moxifloxacin (Moxifloxacin). This compound acts as an orally effective antibacterial agent and is utilized in research concerning acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and infectious pneumonia.